Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

PURPOSE OF REVIEW: Reduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Shizuya, Masuda, Daisaku, Matsuzawa, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Nonstatin Drugs (R. Carmena, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978439/
https://www.ncbi.nlm.nih.gov/pubmed/31974794
http://dx.doi.org/10.1007/s11883-020-0823-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978439/
https://www.ncbi.nlm.nih.gov/pubmed/31974794
http://dx.doi.org/10.1007/s11883-020-0823-5

Ejemplares similares